{
    "clinical_study": {
        "@rank": "154855", 
        "acronym": "RENABLATE-II", 
        "arm_group": {
            "arm_group_label": "Resistant Hypertension", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The RENABLATE-II study is a prospective, multi-center, non-randomized feasibility study of\n      Catheter-Based Renal Denervation to evaluate the safety and effectiveness of the\n      investigational Celsius\u00ae ThermoCool\u00ae RD Multi-electrode Ablation Catheter and Celsius\u00ae\n      ThermoCool\u00ae RDGW Multi-electrode Ablation Catheter and integrated ablation system to treat\n      resistant hypertension."
        }, 
        "brief_title": "RENABLATE-II Feasibility - 157", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Renal Denervation", 
            "Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject has a systolic blood pressure \u2265 140 mmHg based on an average of 3 office\n             blood pressure readings measured according to the BP guidelines.\n\n          2. Subject is adhering to a stable drug regimen of at least 3 different classes of\n             anti-hypertensive medications, including a diuretic (with no changes for a minimum of\n             2 weeks prior to enrollment) at optimal dose and is expected to be maintained for at\n             least 6 months.\n\n          3. Subject is > 18 and < 85 years of age.\n\n          4. Subject agrees to have all study procedures performed, and is competent and willing\n             to provide written, informed consent to participate in this study.\n\n        Key Exclusion Criteria:\n\n          1. A secondary cause of hypertension, e.g. \"white coat\" hypertension (assessed by 24 h\n             ABPM at  physician's discretion), primary aldosteronism, pheochromocytoma, renal\n             artery stenosis, drug induced-hypertension, Adult Polycystic kidney Disease, renal\n             cell carcinoma, pyelonephritis, glomerulonephritis,  coarctation of the aorta,\n             acromegaly, Cushing's Syndrome, Conn's (primary hyperaldosteronism), polyarteritis\n             nodosum, systemic sclerosis, parenchymal kidney disease, obstructive sleep apnoea\n             based on a workup performed within the 12 months preceding enrollment.\n\n          2. Subject has aorto-ilio-femoral artery anatomy not suitable for treatment with the\n             investigational device(s).\n\n          3. Subject has main renal arteries that are < 20 mm in length or < 4 mm in diameter.\n\n          4. Subject has a prior history of any renal artery intervention including but not\n             limited  to balloon angioplasty, stenting , renal denervation or  surgery.\n\n          5. Subject has an estimated glomerular filtration rate (eGFR) of < 45mL/min/1.73m2,\n             using the MDRD formula.\n\n          6. Subject has type 1 diabetes mellitus.\n\n          7. Subject has history of Myocardial Infarction, unstable angina pectoris, or a\n             cerebrovascular accident in the 6 months period prior to enrolment, or documented\n             widespread atherosclerosis, intravascular thrombosis or unstable plaques.\n\n          8. Subject has hemodynamically significant valvular heart disease for which reduction of\n             blood pressure would be considered hazardous."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095691", 
            "org_study_id": "RENABLATE-II"
        }, 
        "intervention": [
            {
                "arm_group_label": "Resistant Hypertension", 
                "description": "Device: Celsius\u00ae ThermoCool\u00ae RD Multi-electrode Ablation Catheter, Celsius\u00ae ThermoCool\u00ae RDGW Multi-electrode Ablation Catheter", 
                "intervention_name": "Renal Sympathetic Denervation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Resistant Hypertension", 
                "intervention_name": "Celsius\u00ae ThermoCool\u00ae RD Multi-electrode Ablation Catheter, Celsius\u00ae ThermoCool\u00ae RDGW Multi-electrode Ablation Catheter", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 24, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Liz Coling", 
                    "phone": "+420 257 271 111"
                }, 
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic", 
                        "zip": "15 030"
                    }, 
                    "name": "Na Homolce Hospital"
                }, 
                "investigator": {
                    "last_name": "Petr Neuzil", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Martina Striteska, MD", 
                    "phone": "+420 224 96 2605"
                }, 
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic", 
                        "zip": "12808"
                    }, 
                    "name": "Charles University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jean-Claude Lubanda, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mario Petruzzi, MD", 
                    "phone": "+39 3474868620"
                }, 
                "facility": {
                    "address": {
                        "city": "Bari", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Generale Regionale"
                }, 
                "investigator": {
                    "last_name": "Massimo Grimaldi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Barbara Joppa", 
                    "phone": "+64 9630 1961"
                }, 
                "facility": {
                    "address": {
                        "city": "Epsom", 
                        "country": "New Zealand", 
                        "state": "Auckland"
                    }, 
                    "name": "Mercy Angiography"
                }, 
                "investigator": {
                    "last_name": "John Ormiston, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitari Clinic de Barcelona"
                }, 
                "investigator": {
                    "last_name": "Manel Sabat\u00e9, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Czech Republic", 
                "Italy", 
                "New Zealand", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, Multi-center, Non Randomized, Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension (RENABLATE-II- 157)", 
        "overall_contact": {
            "email": "lvanderl@its.jnj.com", 
            "last_name": "Liesbeth Vanderlinden"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Czech Republic:  SUKL", 
                "Belgium:  Agence F\u00e9d\u00e9rale des m\u00e9dicaments et des produits de sant\u00e9 (AFMPS)", 
                "Italy:  Agenzia Italiana del Farmaco (AIFA)", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS)", 
                "New Zealand:  Health and Disability Ethics Committees (HDEC)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety of Renal Denervation in patients with resistant hypertension as measured by Adverse Events [Time Frame: 1, 3, 6 months, annually up to 3 years]", 
            "measure": "Renal Denervation Safety", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095691"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Freedom from adverse renal events through 6 months post-procedure.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Reduction of average office based measurements of systolic blood pressure between baseline and 6 months post-procedure.", 
                "measure": "Reduction", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change in office Systolic (SBP) and Diastolic Blood Pressure (DBP) from baseline to 1, 3, 12 months post-procedure.", 
                "measure": "Office Blood Pressure Change", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Incidence of subjects achieving target SBP (<130 mmHg) at 6 months.", 
                "measure": "Target Blood Pressure", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Incidence of changes in medical regimen for high blood pressure and low blood pressure through 6 months post-procedure.\nIncidence of subjects achieving a \u2265 10 mmHg reduction in Systolic Office BP at 1 month, 3 months, 6 months and 12 months post procedure", 
                "measure": "Blood Pressure Changes", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Biosense Webster, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biosense Webster, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}